

Rheumatoid Arthritis

## Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02608112 ML29256

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

**Hoffmann-La Roche**  
Sponsor

**N/A**  
Phase

---

**NCT02608112 ML29256**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>= 18 Years

**Healthy Volunteers**  
No

---